Event Schedule
Event Overview
Instructions for Credit
Thank you for attending this conference. Your feedback is valuable to us.
Registered attendees can earn a maximum of 8.25 CME/CE/ILNA/CPE credits. You will be able to select the amount of credits claimed.
Day 1: 0.00 credits
Day 2: 8.25 credits
Total: 8.25 credits
To claim credits and receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.
Nursing: Please select the ‘Nursing’ credit option.
Pharmacist: Please select the ‘Pharmacy’ credit option.
NABP e-profile number and date of birth (mm/dd/yyyy) is required in your profile. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity. Any Pharmacy credits requested after the 60 days will incur charges.
Physician Associate: Please select the ‘AAPA Category 1’ credit option.
Other Healthcare Professionals: Please select the ‘Other’ credit option.
For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Credits
- AAPA Category 18.25
- IPCE Credits8.25
- Nursing8.25
- Other8.25
- Pharmacy8.25
Universal Activity Number(s)
Pharmacist: JA4008179-0000-26-009-L01-P
Event Details
- Duration
- 8.25 hours
- Start Date
- August 27th, 2026 4:00 PM (EDT)Central: August 27th, 2026 3:00 PMMountain: August 27th, 2026 2:00 PMPacific: August 27th, 2026 1:00 PM
- End Date
- August 28th, 2026 6:30 PM (EDT)Central: August 28th, 2026 5:30 PMMountain: August 28th, 2026 4:30 PMPacific: August 28th, 2026 3:30 PM
Objectives
Discuss how biomarkers and genetics drive treatment and prevention strategies.
Apply the latest advances in the diagnosis, treatment, and management of cancers, including leiomyosarcomas, neurological malignancies, ovarian cancer.
Review the foundational workup of a lung mass, incorporating pathology and pulmonary perspectives within a multidisciplinary approach to diagnosis and management.
Evaluate the emerging role of bispecific antibody therapies following Chimeric Antigen Receptor (CAR)-T cell treatment, including their clinical efficacy, safety profile, and impact on patient outcomes in hematologic malignancies.
Review recent hematology drug approvals, focusing on mechanisms, key clinical data, and implications for patient care.
Implement best practices in survivorship care by designing long-term follow-up strategies for patients who have received CAR-T cell therapy.
Review key supportive care topics, including cognitive changes, integrative medicine, and grief and bereavement, to enhance holistic patient care and outcomes.
Explore the role of cardio-oncology in breast cancer through a case-based approach, focusing on risk assessment, monitoring, and management of treatment-related cardiotoxicity.
Examine the role of GLP-1–based therapies in cancer care, including benefits, risks, and considerations for use in oncology patients.
Inspire and empower the oncology team by reinforcing purpose, resilience, and the collective impact of their work on patient outcomes and care delivery.
Target Audience
Nurse Practitioners/Nurses
Pharmacists
Physician Associates
Physicians
Other Healthcare Professionals
Accreditation
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 8.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Nursing
The Medical Educator Consortium designates this activity for 8.25 ANCC contact hours.
ILNA Coding: The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
Care Continuum (OCN, CBCN, CPHON, A0CNP, ROCN): 2.75 points*
Oncologic Emergencies (OCN, CPHON, AOCNP): 1.5 points*
Professional Practice/Performance (TCTCN, AOCNP, ROCN): 1.75 points*
Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN): 1.5 points*
Roles of the APRN (AOCNP): 1.75 points*
Treatment (OCN, CBCN, AOCNP, CPHON, ROCN): 6.0 points*
Total Points: 8.25
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated is the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of Nursing Continuing Professional Development (NCPD) awarded from this course and may only apply to the credential each nurse is renewing.
Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Pharmacist
This Application-based activity has been approved for 8.25 contact hours (.825 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-26-009-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
Physician Associate
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.